927811-64-1

Basic information

• Product Name: 3-[[5-chloro-2-methoxy-4-(4-morpholinylmethyl)-phenyl]methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one
• Synonyms: 3-[[5-chloro-2-methoxy-4-(4-morpholinylmethyl)-phenyl]methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one
• CAS NO: 927811-64-1
• Molecular Weight: 483.875
• Mol File: 927811-64-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-[[5-chloro-2-methoxy-4-(4-morpholinylmethyl)-phenyl]methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[[5-chloro-2-methoxy-4-(4-morpholinylmethyl)-phenyl]methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one(927811-64-1)
• EPA Substance Registry System: 3-[[5-chloro-2-methoxy-4-(4-morpholinylmethyl)-phenyl]methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one(927811-64-1)

Safety Data

• Hazardous Substances Data: 927811-64-1(Hazardous Substances Data)

Upstream product

• 824-98-6 m-methoxybenzyl chloride 
• 122439-14-9 4-[(3-methoxyphenyl)methyl]morpholine 
• 455-24-3 4-trifluoromethylbenzoic acid 
• 339-59-3 4-(trifluoromethyl)benzoic acid hydrazide 
• 927811-62-9 5-chloro-2-methoxy-4-morpholin-4-ylmethyl-benzaldehyde 
• 927811-61-8 4-[(2-chloro-5-methoxyphenyl)methyl]morpholine 
• 927811-63-0 4-(4-morpholinylmethyl)-5-chloro-2-methoxybenzenemethanol 
• 202823-22-1 5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-(3H)-one 

Relevant articles and documents

3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3, 4-oxadiazol-2(3H)-one, BMS-191011: Opener of large-conductance Ca 2+-activated potassium (maxi-K) channels, identification, solubility, and SAR

Compound 8a (BMS-191011), an opener of the cloned large-conductance, Ca2+-activated potassium (maxi-K) channel, demonstrated efficacy in in vivo stroke models, which led to its nomination as a candidate for clinical evaluation. Its maxi-K channel opening properties were consistent with its structural topology, being derived by combining elements from other known maxi-K openers. However, 8a suffered from poor aqueous solubility, which complicated elucidation of SAR during in vitro evaluation. The activity of 8a in in vivo stroke models and studies directed toward improving its solubility are reported herein. Enhanced solubility was achieved by appending heterocycles to the 8a scaffold, and a notable observation was made that inclusion of a simple amino group (anilines 8k and 8l) yielded excellent in vitro maxi-K ion channel opening activity and enhanced brain-to-plasma partitioning compared to the appended heterocycles.